Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biolen (bicalutamide implant) and radiation in localized prostate cancer
NCT04943536Phase 1Active, not recruiting
- Sponsor
- Alessa Therapeutics
- Start
- Dec 2021
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bicalutamide in prostate adenocarcinoma, sponsored by Alessa Therapeutics. Primary endpoint: Feasibility of replacing systemic androgen therapy with targeted local delivery at 27 months. Started Dec 2021; status: active, not recruiting.
02
Drugs
bicalutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT04943536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04943536.